Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST), a biotechnology company specializing in synthetic DNA, has announced its executives' participation in several upcoming investor conferences. Patrick Finn, Ph.D., president and COO, will join a fireside chat at the Leerink Partners Healthcare Crossroads Conference on May 29 in Austin, TX. Emily Leproust, Ph.D., CEO and co-founder, will present at the William Blair Growth Stock Conference on June 4 in Chicago, IL, at the Jefferies Global Healthcare Conference on June 6 in New York, NY, and will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11 in Miami, FL. The sessions will be webcast live and available on the company's website, with replays accessible for 30 days after the events.
Twist Bioscience (TWST) has launched Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA up to 500 base pairs in length, with no limit on sequence number, enabling high-throughput screening applications. This offering allows for rapid screening of diverse targets for CRISPR and genome engineering, antibody discovery, protein engineering, and more. The customizable fragments have a quick turnaround time, starting at 8 business days, making them versatile for various applications.
Twist Bioscience announced the granting of 87,200 restricted stock units to 26 new employees as inducement for joining the company. The RSUs vest over a 48-month period for each employee, with 25% vesting on the one year anniversary of employment and 1/16 vesting quarterly thereafter.
Twist Bioscience (NASDAQ: TWST) reported a record revenue of $75.3M in the second quarter of fiscal 2024, showing a 25% increase over the same period in fiscal 2023. Orders also grew by 45% to $93.2M. The company increased its revenue guidance for fiscal 2024 to a range of $300M to $304M and its gross margin guidance to 41.5% to 42.0%. Twist Bioscience continues to focus on profitability and aims to improve gross margin to over 50% by the end of fiscal 2025.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
